Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, septembre 01
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Guardant Health Inc
GH
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$159.02
-2.48
-1.54%
À la clôture: Aug 28, 5:00 PM EST
$159.02
-2.48
-1.54%
Pré-ouverture: 8:05 AM EST
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Guardant Health Financials
Guardant Health (GH) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est
Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.
Benzinga Newsdesk
PRO
Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of $(0.44) per share from
Benzinga Newsdesk
PRO
Guardant Health Raises FY2026 Sales Guidance from $1.250B-$1.280B to $1.300B-$1.320B vs $1.271B Est
2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to
Benzinga Newsdesk
PRO
Guardant Health Q1 Adj. EPS $(0.45) Beats $(0.76) Estimate, Sales $301.665M Beat $279.198M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.76) by 40 percent. This is a 8.16 percent increase over losses of $(0.49) per share from the
Benzinga Newsdesk
PRO
Guardant Health Sees FY2026 Sales $1.250B-$1.280B vs $1.238B Est
Guardant Health (NASDAQ:GH) sees FY2026 sales of $1.250 billion-$1.280 billion vs $1.238 billion analyst estimate.
Benzinga Newsdesk
PRO
Guardant Health Q4 Adj. EPS $(0.50) Beats $(0.69) Estimate, Sales $281.266M Beat $271.011M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 28.06 percent. This is a 19.35 percent increase over losses of $(0.62) per share from the
Benzinga Newsdesk
Privacy Manager